PREVENTION OF HEART ALLOGRAFT REJECTION BY MONOCLONAL ANTIBODY TO CD45RB

Abstract

The leukocyte common antigen (LCA) is a protein tyrosine phosphatase and is identified by the CD45 cluster of monoclonal antibodies, CD45 is expressed in high density on cells of hematopoietic lineage and generally is immunoprecipitated as 4 bands (220, 205, 190, and 180 KDa). We have used CD45RB Mab termed "MT3" that binds to a sialic acid dependent epitope to demonstrate to inhibit the heart allograft rejection in mice. Since the CD45 is one of the major targets of antilymphocyte globulin, we assessed the CD45RB mAb for their ability to inhibit alloreactivity in vivo. Although histopathological studies revealed that vasculitis, ischemia, thrombosis and lymphocytes infiltration occurred in all groups, CD4SRB mAb has reasonable inhibitory effect to allograft rejection. These data suggest that the CD45RB may be appropriate target for in vivo immunotherapy.